Gelteq Secures $3.5M Debt Financing to Scale Trials and Commercialization
Gelteq secured USD 3.5 million in debt financing, receiving USD 1.0 million now and USD 2.5 million post-shareholder approval in June 2026, with no repayments due for six months. Proceeds will fund scaling of clinical trials, accelerate nutraceutical commercialization, and boost operational scalability to drive revenue growth in key markets.
1. Financing Details
Gelteq has obtained USD 3.5 million in strategic debt financing, receiving USD 1.0 million on closing and securing an additional USD 2.5 million pending shareholder approval expected in June 2026. The structure includes a six-month repayment holiday, providing near-term growth capital while preserving cash flow.
2. Planned Allocations
The company plans to allocate funds to expand its clinical trial programs for pharmaceutical products and ramp up commercialization of its gel-based nutraceutical offerings. Resources will also support ongoing regulatory pathways and accelerate sales execution across targeted markets.
3. Strategic Impact
This financing is designed to strengthen Gelteq’s operational scalability, enabling the firm to deploy greater resources toward revenue-generating opportunities. The additional capital aims to drive broader market adoption of its proprietary Gelteq® technology and catalyze revenue growth across its product portfolio.